Back

A Breath-Based In Vitro Diagnostics for Lower Respiratory Tract Infection

Chen, D.; Mirski, M. A.; Caton, E. R.; Kiser, K. M.; Haddaway, C. R.; Cetta, M. S.; Chen, S.; Bryden, W. A.; McLoughlin, M.

2023-09-18 intensive care and critical care medicine
10.1101/2023.09.18.23295728
Show abstract

Lower Respiratory Tract Infections (LRTIs) represent the leading cause of death due to infectious diseases. Current diagnostic modalities primarily depend on clinical symptoms and lack specificity, especially in light of common colonization without overt infection. To address this, we developed a noninvasive diagnostic approach that employs BreathBiomics, an advanced human breath sampling system, to detect protease activities induced by bacterial infection in the lower respiratory tract. Specifically, we engineered a high-sensitivity and high-specificity molecular sensor for human neutrophil elastase (HNE). The sensor undergoes cleavage in the presence of HNE, an event that is subsequently detected via Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS). Application of this methodology to clinical samples, breath specimens collected from intubated patients with LRTIs, demonstrated the detection of the cleaved sensor by MALDI-TOF MS. Our findings indicate that this novel approach offers a noninvasive and specific diagnostic strategy for people with LRTIs. O_TEXTBOXSignificance The potential for using human breath for noninvasive disease detection and diagnosis has long been recognized, yet the lack of effective biomolecular sampling technologies has hindered progress. To address this limitation, we developed BreathBiomics, an advanced sampling system designed to efficiently capture biomolecules in human exhaled breath. By focusing on protease dysregulation, an established event induced by bacterial infections, we demonstrated that BreathBiomics can capture proteases and facilitate their subsequent activity-based detection for the diagnosis of LRTI. We verified the assays sensitivity and clinical applicability through empirical studies. Our work marks a significant advancement by providing the first viable pathway for the development of in vitro diagnostic assays leveraging human breath for disease detection and diagnosis. C_TEXTBOX

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Scientific Reports
based on 701 papers
Top 7%
13.1%
2
iScience
based on 74 papers
Top 0.1%
11.6%
3
PLOS ONE
based on 1737 papers
Top 53%
8.6%
4
Clinical Chemistry
based on 14 papers
Top 0.1%
8.6%
5
Science Translational Medicine
based on 40 papers
Top 0.3%
5.5%
6
Genomics, Proteomics & Bioinformatics
based on 10 papers
Top 0.4%
3.1%
50% of probability mass above
7
eLife
based on 262 papers
Top 10%
2.5%
8
European Respiratory Journal
based on 44 papers
Top 2%
2.5%
9
eBioMedicine
based on 82 papers
Top 0.9%
2.5%
10
Frontiers in Medicine
based on 99 papers
Top 7%
2.5%
11
JCI Insight
based on 63 papers
Top 3%
2.4%
12
Critical Care
based on 14 papers
Top 0.8%
2.3%
13
Nature Communications
based on 483 papers
Top 28%
1.9%
14
Cells
based on 14 papers
Top 0.5%
1.9%
15
Applied Sciences
based on 10 papers
Top 0.7%
1.4%
16
Nature
based on 58 papers
Top 6%
1.4%
17
PLOS Computational Biology
based on 141 papers
Top 7%
1.4%
18
American Journal of Respiratory and Critical Care Medicine
based on 23 papers
Top 1%
1.3%
19
Analytical Chemistry
based on 15 papers
Top 0.9%
1.2%
20
Frontiers in Molecular Biosciences
based on 10 papers
Top 0.4%
1.2%
21
Cell Reports Medicine
based on 49 papers
Top 4%
0.9%
22
Biosensors and Bioelectronics
based on 13 papers
Top 0.8%
0.8%
23
Frontiers in Cellular and Infection Microbiology
based on 22 papers
Top 3%
0.8%
24
Journal of Experimental Medicine
based on 10 papers
Top 0.7%
0.8%
25
Gut Microbes
based on 15 papers
Top 1%
0.7%
26
Heliyon
based on 57 papers
Top 13%
0.7%
27
mSphere
based on 27 papers
Top 3%
0.7%
28
mBio
based on 34 papers
Top 3%
0.7%
29
Viruses
based on 79 papers
Top 7%
0.7%
30
Bioinformatics
based on 24 papers
Top 2%
0.7%